Home › Funds › Freestone Grove Partners LP › ABT

Freestone Grove Partners LP position in ABT

ABBOTT LABORATORIES · Health Care

Freestone Grove Partners LP reported holding 1,372,846 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$124.6M, representing 0.80% of its reported portfolio and ranking #12 among its reported holdings. Freestone Grove Partners LP has disclosed ABT holdings in 3 of the last 6 reported quarters, going back to Q1 2025.

Latest position (Q2 2026)1.37M sh
Reported value held$124.57M
Portfolio Weight0.80%
First reportedQ1 2025
Last changeNew
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Freestone Grove Partners LP's ABT position evolved

Freestone Grove Partners LP first disclosed a stake in ABT in Q1 2025 at 90,883 shares (US$12.1M). The position peaked in Q2 2025 at 918,608 shares, worth US$124.9M. Across 3 filings, Freestone Grove Partners LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,372,846 shares valued at US$124.6M. Notable position changes include a 911% increase in Q2 2025 (shares fell 1% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 90.88K $12.06M New
Q2 2025 918.61K $124.94M Add
Q2 2026 1.37M $124.57M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Freestone Grove Partners LP held ABT?

Freestone Grove Partners LP has disclosed ABT holdings in 3 of the last 6 reported quarters, going back to Q1 2025.

What is Freestone Grove Partners LP's current position in ABT?

As of Q2 2026, Freestone Grove Partners LP holds 1.37M shares of ABT (ABBOTT LABORATORIES), valued at $124.57M, representing 0.80% of its reported portfolio and ranking #12.

Has Freestone Grove Partners LP been buying or selling ABT?

In the latest 13F filing (Q2 2026), Freestone Grove Partners LP newly opened its position in ABT. The position peaked in Q2 2025 at 918.61K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.